Mode
Text Size
Log in / Sign up
N/A N=42 Treatment

755nm Alex Laser for Treatment of Pigmented and Vascular Lesions and Scars

Benign Pigmented and Vascular Lesions and Scars

Enrolled (actual)
42
Serious AEs
0.0%
Results posted
Dec 2020
Primary outcome: Primary: Clearance Based on Photographic Scale — 2; 2; 4; 7 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
755nm Alex laser (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Cynosure, Inc.
Primary completion
Dec 2013

Outcome Measures

OutcomeResultp-value
PRIMARY
Clearance Based on Photographic Scale
2; 2; 4; 5
PRIMARY
Clearance Based on Photographic Scale
2; 2; 4; 5

Summary

Evaluation of the safety and efficacy of the 755nm Alex laser for the treatment of benign pigmented and vascular lesions and scars

Eligibility Criteria

Inclusion Criteria

  • Healthy male or female subjects between 18 and 85 years of age.
  • Subjects with Fitzpatrick skin types I to VI.
  • Subjects who have unwanted pigmented lesions, vascular lesions, striae and/or hypertrophic or atrophic scars
  • Subject who are willing to consent to participate in the study.

4.2 Exclusion Criteria

  • Subject who will not be photographed or who will not cooperate with the post treatment care and follow up schedule
  • Hypersensitive to light exposure.
  • Active localized or systemic infections.
  • Taking medication for which sunlight is a contraindication.
  • History of squamous cell carcinoma or melanoma.
  • History of keloid scarring.
  • Use of oral isotretinoin (Accutane®) within 12 months of initial treatment or during the course of the study. Note: Skin must regain its normal degree of moisture prior to treatment.
  • Prior treatment with laser or other devices in treatment area within 3 months
  • History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or use of immunosuppressive medications.
  • Subjects who are pregnant, have been pregnant within the last 3 months, are currently breast feeding or are planning a pregnancy within the study period.
  • Subjects that the physician determines ineligible based on standard of care treatment.

-

-

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01745627). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search